From the book
How to read the evidence
Each numbered answer ends with an evidence scope: what kind of knowledge supports the answer, whom it concerns, and which outcome it addresses. A strong result for one use does not establish a different use. Relief of pain, a lower blood test, fewer heart attacks, and longer life are different outcomes.
ROBUST HUMAN TRIALS means reasonably convincing intervention evidence for the stated population and outcome. It does not mean everyone should take the treatment. LIMITED or SMALL HUMAN STUDIES means the available trials leave important uncertainty.
OBSERVATIONAL means an association was measured without random assignment. A finding can be consistent and important while still being affected by confounding, selection, or reverse causation. A risk marker is not automatically a treatment target.
PRECLINICAL means cells or animals. NOT DEMONSTRATED means that the proposed clinical benefit has not been established; it does not prove that benefit is impossible. A negative trial is described for the population and endpoint it actually tested.
GUIDELINE-BASED, REGULATORY STATUS, and CLINICAL JUDGMENT answer different questions. A recommendation is not a trial result. FDA approval is indication-specific. A spending preference or forecast is not given a clinical efficacy grade.
“Hype” describes a gap between a marketing promise and its support. It is not an evidence category. The text may criticize that gap, but the evidence scope explains the underlying uncertainty without confusing unproven with disproven.
The scopes are editorial summaries, not a formal GRADE systematic review. Look at the study type, the population, the outcome, and the limitations together. Notes and sources at the back identify the principal research and provide question-linked references for important revised guidance.
The longevity field guide
Four visual frameworks to use alongside the 433 evidence-graded answers
01 THE EVIDENCE LADDER
HUMAN OUTCOME TRIALS → OBSERVATIONAL DATA → SMALL HUMAN STUDIES → ANIMAL AND CELL STUDIES. Each answers a different question. Strong evidence for one outcome does not prove a different outcome.
02 THE MONEY FILTER
FIRST: blood pressure, smoking, lipids, exercise, sleep, preventive care. NEXT: tests or treatments that change a decision. LAST: expensive devices, infusions, and experimental compounds. Ask: What improves, for whom, and at what risk?
03 THE TEST-TO-ACTION PATH
QUESTION → Is the test validated? → Would the result change care? → Are false positives understood? → Discuss with your clinician → Act and reassess.
04 THE HEALTHSPAN EQUATION
Years alive ≠ years well. Protect physical function, cognition, independence, and relationships. No single biomarker or gadget measures the whole person.
Evidence grade (draft mapping)
Each answer’s printed evidence scope is grouped into one of nine grade codes so you can scan and filter. This grouping is a draft mapping made by the site from the book’s own wording; the evidence scope printed in the book always takes precedence. Answers whose wording does not fit a single code show “Grade pending”.
- ARobust human trials
- BLimited or small human studies
- CObservational
- DPreclinical / mechanistic
- EEstablished clinical knowledge
- GGuideline-based / consensus
- RRegulatory status
- JClinical judgment / author synthesis
- FNot demonstrated / insufficient
- Grade pendingNot yet mapped